Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Hepatobiliary disorders – page 29

  • 356 clinical trials
  • 141 recruiting
  • 239 conditions
  • 25 countries

Conditions in this area

239 conditions with trials, the busiest first

Hepatocellular carcinoma89Cholangiocarcinoma38Hepatic cirrhosis25Metabolic dysfunction-associated steatohepatitis22Colorectal cancer20Non-alcoholic steatohepatitis17Chronic hepatitis B16Hepatitis D14Primary biliary cholangitis13Cholangitis sclerosing12Endometrial cancer12Non-small cell lung cancer12Alpha-1 antitrypsin deficiency11Gastric cancer11Malignant melanoma11Biliary neoplasm10Hepatitis B10Breast cancer9Ovarian cancer9Bile duct cancer8Gallbladder cancer8Hepatic cancer8Pancreatic carcinoma8Adenocarcinoma pancreas7+215

Clinical trials in Hepatobiliary disorders

356 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

356 clinical trials

Hepatic encephalopathy

Not recruiting
Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Rifaximin
  • Sponsor:Salix Pharmaceuticals Inc.

Cholangiocarcinoma+1

Not recruiting
Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Lisata Therapeutics Inc.

Metastases to liver

Not recruiting
InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Chimeric Monoclonal Antibody Against Carcinoembryonic Antigen Conjugated To Fluorochrome Bm-104
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Metabolic dysfunction-associated steatohepatitis+1

Not recruiting
Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efinopegdutide
  • Sponsor:Merck Sharp & Dohme LLC

Primary biliary cholangitis+1

Not recruiting
InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Linerixibat
  • Sponsor:Glaxosmithkline Research & Development Limited

Metabolic dysfunction-associated steatohepatitis+3

Not recruiting
Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Semaglutide
  • Sponsor:Region Midtjylland

Hepatocellular carcinoma

Not recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Klinikum Der Universitat Munchen AöR

Cholestatic pruritus

Not recruiting
Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Maralixibat Chloride
  • Sponsor:Mirum Pharmaceuticals Inc.

Cholangitis sclerosing

Not recruiting
Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Norucholic Acid
  • Sponsor:Dr. Falk Pharma GmbH

Metabolic dysfunction-associated liver disease

Not recruiting
Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Quercetin
  • Sponsor:Amsterdam UMC

Hepatocellular carcinoma

Not recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Assistance Publique Hopitaux De Paris

Chronic hepatitis B

Not recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Elebsiran
  • Sponsor:Vir Biotechnology Inc.

Substances studied in this area

The therapies tested most often in Hepatobiliary disorders trials.

Durvalumab37 clinical trialsBevacizumab29 clinical trialsAtezolizumab27 clinical trialsCisplatin26 clinical trialsLenvatinib22 clinical trialsTremelimumab22 clinical trialsGemcitabine20 clinical trialsInfliximab15 clinical trialsMycophenolate Mofetil15 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.